Real‐world practice and Expectation of Asia‐Pacific physicians and patients in <i>Helicobacter Pylori</i> eradication (REAP‐HP Survey)

Chuah, Yoen-Young; Wu, Deng‐Chyang; Chuah, Seng‐Kee; Yang, Jyh‐Chin; Lee, Tzong‐Hsi; Yeh, Hong-Zen; Chen, Chan-Lin; Liu, Yu-Hwa; Hsu, Ping‐I

doi:10.1111/hel.12380

Cited by 16 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A real-world study indicated that the expectation of eradication rate was over 90% by patients and about 86% by physicians. 33 Apparently, clinical practice neither satisfied public expectations nor met physicians' needs.…”

Section: Discussionmentioning

confidence: 99%

Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross‐sectional survey

Zhang

Liu

et al. 2022

J of Digest Diseases

View full text Add to dashboard Cite

Objective: To investigate the management of Helicobacter pylori (H. pylori) infection by gastroenterologists from secondary and tertiary hospitals in Shandong Province, China, where there is a high prevalence of H. pylori infection.Methods: A questionnaire-based, stratified sampling survey was conducted from June 1 to August 30, 2021. The ratio of secondary to tertiary hospitals was set at 2:1. An electronic questionnaire was sent to the gastroenterologists via the WeChat platform.Results: A total of 89.09% (1053/1182) gastroenterologists were included. Overall, 34.19% and 60.59% of gastroenterologists recommended screening for and treating H. pylori infection in patients without any competing factors. The most preferred testing method in secondary and tertiary hospitals was the 13 C-urea breath test (53.92% and 80.48%), but the reexamination rate of results close to the cut-off value was low (55.10% and 59.48%). Gastroenterologists preferred bismuth-containing quadruple therapy (secondary and tertiary hospitals: 96.67% and 98.53%), but the antibiotic combination prescribed for patients with penicillin allergy was suboptimal in secondary hospitals.The overall post-treatment follow-up rate was 64.58%, and gastroenterologists in secondary hospitals were more proactive than those in tertiary hospitals (69.41% vs 60.04%, P = 0.001). Less than 80% of gastroenterologists emphasized the importance of post-treatment reexamination to their patients. Only a minority of gastroenterologists in secondary and tertiary hospitals (30.79% and 34.36%) achieved acceptable eradication rates (exceeding 80%).Conclusions: Deficiencies exist in gastroenterologists from secondary and tertiary hospitals, and the H. pylori eradication rate is relatively low. Training programs for gastroenterologists are warranted to strengthen their comprehension of guidelines.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross‐sectional survey

Zhang

Liu

et al. 2022

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

“…The questionnaire encompassed eight questions focusing on following categories: age, gender, specialty, location of medical practice, types of hospital, most commonly prescribed regimen, factor that causes the most concern when prescribing first line anti-H. pylori regimen (eradication rate, side effect, cost, number of pills, duration of regimen, convenience, and other factors), and the accepted minimal eradication rate of a first-line anti-H. pylori regimen (≥95%, ≥90%, ≥85%, ≥80%, ≥75%, ≥70%, ≥65%, ≥60%, and others). 18 The mean accepted minimal eradication rate of gastroenterologists was defined as the mean value of accepted minimal eradication rates chosen by the…”

Section: Methodsmentioning

confidence: 99%

“…In 2015, we distributed the same questionnaire to the Taiwanese gastroenterologist who attended the Asia-Pacific Digestive Week 2015, and the Survey results had been reported. 18 In the current study, we compared the survey data between Taiwanese gastroenterologists in 2020 and those surveyed in 2015.…”

Section: Differences In H Pylori Treatment Survey Data Between Gastro...mentioning

confidence: 99%

“…REAP-HP study (Real-world practice and Expectation of Asia-Pacific physicians and patients in H. Pylori eradication) was the pioneer study investigating the expectation and preference of physicians across Asia-Pacific in H. pylori eradication in 2015. 18 The study showed that the top five most commonly used regimens in Asia-Pacific region were 7-day clarithromycin-based standard triple therapy (50.4%), 14-day clarithromycin-based standard triple therapy (31.0%), 10-day sequential therapy (6.1%), 14day bismuth quadruple therapy (3.9%), and 14-day hybrid therapy (3.6%). This survey is a follow-up study of REAP-HP exploring the possible changes of expectation and preference among gastroenterologists in Taiwan from 2015 to 2020.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

REAP‐HP survey 2020: Comparing the real‐world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020

Chuah

et al. 2022

Helicobacter

Self Cite

View full text Add to dashboard Cite

Background: REAP-HP study (Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication) was the pioneer study investigating the expectation and preference of physicians across Asia-Pacific in H. pylori eradication in 2015. This study is the first follow-up study of REAP-HP in Taiwan. Aims: (1) To investigate the preference in regimens for the first-line anti-H. pylori therapy of Taiwanese gastroenterologist in 2020, (2) To survey the factor that cause the most concern when prescribing anti-H. pylori regimens in clinical practice, and (3) to compare REAP-HP survey data in 2020 and those surveyed in 2015 regarding the abovementioned end-points. Methods: A questionnaire for H. pylori eradication survey of physicians was distributed to the gastroenterologists who attended the Taiwan Digestive Disease Week 2020. Data of most commonly used first-line anti-H. pylori regimens and concerned factors when prescribing anti-H. pylori regimens between 2015 and 2020 were compared.

show abstract

“…3,4 A recent survey for H. pylori eradication therapy revealed that 7-day standard triple therapy remained the most popular regimen in the Asia-Pacific region. 5 Most physicians in Taiwan, Japan, and Korea adopted 7-day and 14-day standard triple therapies in the first-line treatment of H. pylori infection (62% and 21%, 100% and 0%, and 81% and 7%, respectively). However, the prevalence of antibiotic resistance markedly increases with time worldwide, and the eradication rate of standard triple therapy has decreased to less than 80% in most countries worldwide.…”

mentioning

confidence: 99%

Tetracycline‐levofloxacin versus amoxicillin‐levofloxacin quadruple therapies in the second‐line treatment of Helicobacter pylori infection

et al. 2021

View full text Add to dashboard Cite

Background The Maastricht V/Florence Consensus Report recommends amoxicillin‐fluoroquinolone triple or quadruple therapy as a second‐line treatment for Helicobacter pylori infection. An important caveat of amoxicillin‐fluoroquinolone rescue therapy is poor eradication efficacy in the presence of fluoroquinolone resistance. The study aimed to investigate the efficacies of tetracycline‐levofloxacin (TL) quadruple therapy and amoxicillin‐levofloxacin (AL) quadruple therapy in the second‐line treatment of H. pylori infection. Methods Consecutive H. pylori‐infected subjects after the failure of first‐line therapies were randomly allocated to receive either TL quadruple therapy (tetracycline 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, and tripotassium dicitrato bismuthate 300 mg QID) or AL quadruple therapy (amoxicillin 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, and tripotassium dicitrato bismuthate 300 mg QID) for 10 days. Post‐treatment H. pylori status was assessed 6 weeks after the end of therapy. Results The study was early terminated after an interim analysis. In the TL quadruple group, 50 out of 56 patients (89.3%) had successful eradication of H. pylori infection. Cure of H. pylori infection was achieved only in 39 of 52 patients (69.6%) receiving AL quadruple therapy. Intention‐to‐treat analysis showed that TL quadruple therapy achieved a markedly higher eradication rate than AL quadruple therapy (95% confidence interval: 4.8% to 34.6%; p = 0.010). Further analysis revealed that TL quadruple therapy had a high eradication rate for both levofloxacin‐susceptible and resistant strains (100% and 88.9%). In contrast, AL quadruple therapy yielded a high eradication for levofloxacin‐susceptible strains (90.9%) but a poor eradication efficacy for levofloxacin‐resistant strains (50.0%). The two therapies exhibited comparable frequencies of adverse events (37.5% vs 21.4%) and drug adherence (98.2% vs 94.6%). Conclusions Ten‐day TL quadruple therapy is more effective than AL quadruple therapy in the second‐line treatment of H. pylori infection in a population with high levofloxacin resistance.

show abstract

Real‐world practice and Expectation of Asia‐Pacific physicians and patients in Helicobacter Pylori eradication (REAP‐HP Survey)

Abstract: It is time for physicians in Asia-Pacific countries to adopt newer and more efficacious anti-H. pylori regimens to meet the Kyoto consensus recommendation and their patients' expectations.

Cited by 16 publications

References 48 publications

Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross‐sectional survey

Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross‐sectional survey

REAP‐HP survey 2020: Comparing the real‐world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020

Tetracycline‐levofloxacin versus amoxicillin‐levofloxacin quadruple therapies in the second‐line treatment of Helicobacter pylori infection

Contact Info

Product

Resources

About